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Abstract
Background: The metabolic syndrome is associated with increased risk for both diabetes and coronary artery
disease, which insulin resistance alone does not satisfactorily explain. We propose an additional and
complementary underlying mechanism of glucocorticoid resistance.
Results: Using acanthosis nigricans (AN) and skin vasoconstrictor (SVC) response to topically applied
beclomethasone dipropionate as markers of insulin and glucocorticoid resistance, respectively, we compared
anthropometric, biochemical, pro-inflammatory markers and the SVC response in subjects with AN in two studies:
STUDY 1 was used to compare subjects with AN (Grade 4, n = 32), with those without AN (n = 68) while STUDY 2
compared these responses among a cross-section of diabetic patients (n = 109) with varying grades of AN (grade
0, n = 30; grade 1, n = 24; grade 2, n = 18; grade 3, n = 25; grade 4, n = 12).
Findings: In both studies there was an inverse relationship between AN Grade 4 and the SVC response, (P <
0.001). In STUDY 1, AN Grade 4 was associated with age, waist circumference, BMI, fasting blood glucose, plasma
lipids and hs-CRP (P < 0.05). SVC was an independent predictor of CRP and those with combined AN and a
negative SVC response, CRP levels were highest. In Study 2 when the SVC response in subjects with type 2
diabetes mellitus with varying degrees of AN was studied, it showed that for any degree of AN, the SVC response
is more likely to be negative and was independent of gender and ethnicity.
Conclusion: An absent SVC response represents a new biomarker for the metabolic syndrome and the
exaggerated inflammatory response, which characterizes the metabolic syndrome, may be an outcome of deficient
glucocorticoid action in vascular tissue.
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Introduction
Cardiovascular disease, the leading cause of death in
developed countries for many decades, is gaining fresh
momentum from the pandemic of obesity which is an
emergent major public health problem in developing
countries globally [1]. The long recognized association
between cardiovascular disease and obesity [2] became
clearer in 1988 when Reaven [3] consolidated the concept
proposing that insulin resistance with compensatory
hyperinsulinemia was a fundamental pathogenetic
mechanism. Type 2 diabetes mellitus (T2DM), hyperten-
sion, dyslipidemia and obesity are, independently and
collectively, consistently associated with the hyperinsuli-
nemic - insulin resistance syndrome or what is now com-
monly referred to as the metabolic syndrome (MS) and
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tively, in risk for T2DM and cardiovascular disease [4].
It is widely accepted that insulin resistance-hyperinsuli-
nemia is a common thread in the MS. However several
features such as mood and sleep disturbances, a pro-
thrombotic tendency and elevated levels of inflammatory
markers have a consistent yet largely unexplained relation-
ship to insulin resistance so that the full understanding of
the dysglycaemia-cardiovascular connection is far from
complete [5,6].
A growing body of evidence suggests obesity, per se,
may be an inflammatory condition [7] and persons with
T2DM, MS or obesity exhibit more pronounced and
longer-lasting inflammatory responses to challenge than
metabolically normal controls [8]. Chronic inflammation
might therefore be the prime mover and common antece-
dent of both T2DM and atherosclerosis [7-9]. What
accounts for the loss of control of inflammation? Is it as
Kolb and Mandrup-Poulsen [8] proposed, “a deficiency of
counter-regulatory circuits to inflammation and metabolic
stress"? Or is it the over-riding presence of obesity which
drives inflammation to impair insulin signaling mechan-
isms and confer insulin resistance [10]?
Cortisol, the naturally occurring glucocorticoid in man
and primates, plays a central role in the regulation of
inflammation, the immune system, intermediary metabo-
lism, the stress response and the cardiovascular system
[11]. Genetic susceptibility to cardiovascular disease has
been linked to polymorphisms of the glucocorticoid
receptor gene which in the case of haplotype 3, a com-
mon genetic variant, gives rise to a highly active pro-
inflammatory system as evidenced by serum C-reactive
protein (CRP) which is attributed to diminished sensitiv-
ity to cortisol[12]. Thus despite mounting evidence for
increased cortisol production [13] and increased cortisol
regeneration [14] in the metabolic syndrome. we postu-
lated that cortisol bioactivity is concomitantly diminished
in MS as a result of diminished glucocorticoid receptor
sensitivity.
To test this hypothesis, we have exploited the human
skin because of its ability to exhibit both insulin resistance,
(evidenced by the presence of acanthosis nigricans, AN)
[15] and glucocorticoid resistance (evidenced by a failed
skin vasoconstrictor (SVC) response to topically applied
glucocorticoid) [16] and further explored the relationship
of these skin markers to inflammation as measured by
highly sensitive C-reactive protein (CRP).
Methods and subjects
Two studies were undertaken. All subjects gave
informed, written consent and approval to conduct
these studies was obtained from the ethics committee of
The University of The West Indies.
DESIGN: Study 1 used a case-control design. Study
2 used a cross-sectional design with convenience
sampling.
Sample size
In the calculation of sample size, the alpha error was set
to 0.05 and beta to 0.2 (power of 80%). Calculations
were based on an odds ratio of 5 (that is, subjects with
acanthosis nigricans would be 5 times less likely to
respond to topical glucocorticoids) and the aim was to
enlist twice as many subjects with acanthosis nigricans
as those without. From a prior study, 10% of controls
had no blanching response to the skin vascoconstrictor
(SVC) assay [16]. Using these values, it was determined
that 30 subjects with acanthosis nigricans and 60 with-
out this particular feature were required.
Subject selection
STUDY 1 compared subjects at the extreme ends of the
spectrum for the physical finding of AN by selecting for
comparison those with severe (grade 4) and normal
healthy controls without any degree of AN around the
neck (grade 0). Grading of severity was based on criteria
by Burke et al [15]. Subjects were drawn from the hospi-
tal outpatient clinic. Those with AN were recruited as
they presented at the diabetic clinic and included patients
as well as relatives accompanying them, who may have
had no knowledge of their diabetic state. Subjects with-
out AN were drawn from hospital staff, who denied any
history of major medical problems.
STUDY 2 used a cross-sectional design to compare
subjects with T2DM who were differentiated by the
grade of acanthosis nigricans present at the neck, which
was scored 0-4 using criteria of Burke et al [15]. In
study 2, two subjects refused the SVC assay out of the
109 sampled.
Investigations
All subjects completed a simple questionnaire, which
provided data on age, gender, ethnicity and the presence/
absence of T2DM. Patients were considered diabetic if
the fasting blood glucose concentration was > 126 mg/dl
or if they responded “yes” to having T2DM on the ques-
tionnaire. In addition, anthropometric measurements
including weight, height, and waist circumference were
measured. Fasting blood samples were taken, processed
and stored at -20°C for subsequent biochemical analyses.
Blood levels of TNF-alpha, IL-1, IL-6 were determined by
ELISA (GenWay, Biotech, Inc. San Diego) and hs-CRP,
plasma glucose and serum triglyceride were measured
using a dry chemistry analyzer (Johnson and Johnson
Vitros 250 Ortho-Clinical Diagnostics Inc. NY, USA)
with the appropriate quality controls.
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The SVC assay was performed according to method
described by Brown et al [16]. The test and control
solutions were beclomethasone dipropionate (Sigma)
dissolved in 95% ethanol to make a concentration of
1000 μg/ml (10-fold higher than that in the original cita-
tion) and 95% ethanol were stored at 4
0 C until time of
use. Two circular outlines on the flexor aspect of the
forearm were obtained using double-sided adhesive tape
with 2 cm diameter holes. Ten μlo fe i t h e rt e s to rc o n -
trol solution was applied at random to these sites,
allowed to dry, occluded with plastic wrap for 16 hours
and 2 hours later observed for blanching under fluores-
cent light by a trained observer, who was blind to the
acanthosis nigricans score and the randomized site of
application of test solutions.
Statistical analyses
The relationships of AN (presence/absence) to the SVC
response (presence/absence) or to ethnicity were analyzed
by the chi squared test. Other data were analyzed by the
Students t- test or Mann Whitney-U test as appropriate.
In study 1, CRP was not normally distributed but had lin-
ear relation with parameters measured. A generalized lin-
ear model was constructed with serum CRP as outcome
variable and variables having significant univariate rela-
tionship with CRP as independent variables. Data was ana-
lyzed using SPSS version 12 for windows.
Results
Study 1
Baseline characteristics
A total of 100 patients were recruited with mean (SD) age
29.90 (11.87) years, weight 72.99 (21.09) Kg, BMI 25.91
(7.41) kg/m
2. There were 44 males. A SVC response of
grade > 0 to topical steroid was demonstrated in 58% of
subjects. Of the 100 patients recruited, 68 had no acantho-
sis nigricans and 32 had grade 4 acanthosis nigricans.
Table 1 shows a comparison of demographic variables and
the SVC assay in subjects with and without acanthosis
nigricans.
Ethnicity and AN and SVC
Tables 2, 3 show that in Study 1 there appears to be a
greater tendency for Afro-Caribbeans to have AN grade 4
and an SVC response of grade 0, however the sample of
Afro-Caribbeans controls (n = 5) and of “others’ (n = 10)
would have precluded meaningful analysis. Tables 4, 5
summarizes the relationships between AN, SVC and eth-
nicity for all grades of AN and for which there was no
apparent ethnic influence on SVC.
AN and SVC
In Study 1, while 76% of those without AN responded with
a positive SVC only 19% of subjects with AN grade 4
showed a similar response. Figure 1(a) shows that in Study
1 there is an obvious tendency for AN grade 4 subjects to
have SVC response of grade 0. This relationship is highly
significant (Kendall’s tau -0.464,. p < 0.001).
CRP and AN and SVC
Table 6 shows the relationship between inflammatory
markers for those with and without acanthosis nigricans.
The level of hs-CRP was elevated in subjects with AN
grade 4. There was no relationship between IL-1, IL-6,
and TNF-alpha between cases and the controls. How-
ever CRP was related to baseline plasma glucose and
serum triglyceride levels.
For the 100 subjects in study 1 there was significant
correlation between CRP and the following variables
(rho, p < 0.001): age (0.475), waist circumference
(0.451), weight (0.397), AN (0.522), SVC graded as zero
or above zero (-0.355). The following variables also had
significant correlations with CRP (rho, p): glucose
(0.226, 0.037), triglycerides (0.347, 0.001). CRP was not
related to ethnicity (p = 0.633) or to any other para-
meters assessed during the study.
Table 1 Demographic and physiologic variables in
subjects with acanthosis nigricans (Grade 4) and without
acanthosis nigricans (GRADE 0), N = 100
Parameter Mean (SD)
Controls
(Acanthosis
Grade 0)
N=6 8
Acanthosis
Nigricans
Grade 4
N=3 2
p
Age (years) 24.36 (5.44) 41.50 (13.32) < 0.001
Weight (Kg) 63.02 (14.10) 94.19 (17.49) < 0.001
Waist Circumference (cm) 78.29 (11.34) 112.02 (13.21) < 0.001
Height (cm) 169.78 (10.06) 164 (10.51) 0.010
BMI (kgm
-2) 21.66 (3.40) 34.96 (5.16) < 0.001
N (%)*
Males 35 (52) 9 (28) 0.033
Ethnicity
Afros/Others 15 (22) 14 (44)
Indos 53 (78) 18 (56) 0.026
SVC assay response
ABSENT 16 (24) 26 (81)
PRESENT 52 (76) 6 (19) < 0.001
Abbreviations: SVC = Skin vasoconstrictor assay to topical beclomethasone
BMI = Body mass index; Afros = Africans; Indos = East Indians;
* = column percentages
Table 2 The relationship between ethnicity and
acanthosis nigricans in Study 1 (N = 100)
AN Grade 4 ETHNICITY Total
AFRO INDO OTHER
Controls (No Acanthosis) 5 (29.4) 53 (74.6) 10 (83.3) 68 (68.0)
AN Grade 4 12 (70.6) 18 (25.4) 2 (16.7) 32 (32.0)
Total 17 71 12 100
Teelucksingh et al. Cardiovascular Diabetology 2012, 11:31
http://www.cardiab.com/content/11/1/31
Page 3 of 10Multivariate analysis with CRP as outcome variable
showed that age, triglycerides and SVC were indepen-
dent predictors of serum CRP (Table 7).
Figure 2 shows that in the subgroup with AN grade 4
and the absence of an SVC, CRP was markedly elevated.
F i g u r e s3 ,4 ,5a n d6s h o wt h ec l i n i c a lg r a d i n go f
acanthosis nigricans as defined by Burke et al. [15].
Study 2
In order to elucidate the relationship of AN to SVC in
more detail we studied a cross-section of diabetic
patients with varying grades of AN. Of the 109 subjects
studied 30 had AN (grade 0) and the other 79 had AN
classified as (N = number): grade 1 (N = 24), 2 (N =
18), 3 (N = 25), 4 (N = 12). Patients with AN grade 0
vs. greater than 0 had mean (SD) age 58.97 (11.54) vs.
55.61 (10.74) years, p = 0.168; weight 71.70 (17.13) vs.
80.63 (18.66), p = 0.028; waist circumference 94.88
(10.37) vs. 105.60 (18.10) cm, p = 0.003; BMI 26.41
(6.18) vs. 29.51 (6.44) kilogram per square metre, p =
0.022. There were 40 males and 62 patients were of
Asian-Indian ethnicity. Tables 4 and 5 show that there
was no difference between ethnic groups in AN or SVC
response. Figure 1(b) shows that there was also a highly
significant trend for subjects with high grade AN to
have a low grade SVC response: Kendall’s tau -0.487, p
< 0.001. The magnitude of the test of trend was similar
in both Study 1 and Study 2.
Discussion
Acanthosis nigricans (AN) was first recognized more
than 100 years ago in association with internal malig-
nancy. In 1976, in a landmark study Kahn et al [17]
described what has become today, its commonest asso-
ciation - the link with insulin resistance and type 2 dia-
betes. Thus individuals with AN are more likely to
display risk factors for type 2 diabetes whatever their
ethnic or geographic origin [18,19].
Fifty years ago, it was observed in the course of treating
skin diseases with topical glucocorticoids that pallor of
the surrounding skin occurred [20], an observation that
has formed the basis of the skin vasoconstrictor assay
(SVC). Traditionally used to evaluate the potential effi-
cacy of newer topical glucocorticoid agents, workers have
explored the potential of this bioassay to assess glucocor-
ticoid sensitivity as a pathogenetic mechanism for disease
[16,21].
Individual responsiveness to topically applied glucocor-
ticoid varies considerably such that there are individuals
who respond with an intense degree of pallor and others
who only barely do so or not at all [22]. In a previous
study [23] we were intrigued by the heterogeneity of this
biologic response to topically applied glucocorticoid and
asked whether a lack of response reflected a more gener-
alized insensitivity to glucocorticoids. We demonstrated
that patients defined as having asthma resistant to stan-
dard therapeutic doses of systemic glucocorticoid were
more likely to demonstrate reduced skin vasoconstrictor
responsiveness to potent topically applied glucocorticoid
[16]. These findings supported the concept that topical
glucocorticoid resistance was an indicator a more gener-
alised phenomenon. In further work, topically applied
progesterone or aldosterone failed to produce a SVC
response and additionally, the response to potent gluco-
corticoid was abolished by specific glucocorticoid recep-
tor blocking agents [24]. These observations permitted
the conclusion that the SVC response is specifically glu-
cocorticoid receptor mediated and its absence may point
to evidence of disturbance of glucocorticoid pharmacody-
namics and receptor activation rather than altered
Table 3 The relationship between ethnicity and SVC in
Study 1 (N = 100)
SVC Response ETHNICITY Total
AFRO INDO OTHER
0 13 (76.5) 25 (35.2) 4 (33.3) 42 (42.0)
1 0 (0.0) 1 (1.4) 0 (0.00) 1 i(1.0)
2 0 (0.00) 1 (1.4) 1 (8.3) 2 (2.0)
3 3 (17.6) 10 (14.1) 0 (0.00 13 (13.0)
4 1 (5.9) 34 (47.9) 7 (58.3) 42 (42.0)
TOTAL 17 71 12 100
Table 4 The relationship between ethnicity and
acanthosis nigricans in Study 2 (N = 107)
Acanthosis Nigricans Graded ETHNICITY Total
AFRO INDO OTHER
0 9 (28.1) 19 (28.4) 2 (20.0) 30 (27.5)
1 6 (18.8) 16 (23.9) 2 (20.0) 24 (22.0)
2 6 (18.8) 10 (14.9) 2 (20.0) 18 (16.5)
3 7 (21.9) 17 (25.4) 1 (10.0) 25 (22.9)
4 4 (12.5) 5 (7.5) 3 (30.0) 12 (11.0)
TOTAL 32 67 10 109
Table 5 The relationship between ethnicity and SVC in
Study 2 (N = 107).
SVC Response ETHNICITY Total
AFRO INDO OTHER
0 19 (59.4) 36 (54.5) 5 (55.6) 60 (56.1)
1 4 (12.5) 5 (7.60 0 (0.00 9 (8.4)
2 1 (3.1) 1 (1.5) 1 (11.1) 3 (2.8)
3 3 (9.4) 6 (9.1) 1 (11.1) 10 (9.3)
4 5 (15.6) 18 (27.3) 2 (22.1)’ 25 (23.4)
TOTAL 32 66 9 107
See text for further details
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this idea, there are data which have linked variation in
skin vasoconstrictor responsiveness to polymorphism in
the glucocorticoid receptor gene [25].
In the current study, we have now demonstrated a
novel clinical observation linking AN to the absence of
the SVC response. Thus the greater the degree of AN,
the less likely was there an SVC response to beclometha-
sone dipropionate. There is a number of possible expla-
nations for this finding. Firstly, in AN, the skin is
thickened and an absent biologic response could simply
be the result of poor bioavailability across thickened skin.
Against this idea would be the fact that the agent used in
this study, beclomethasone dipropionate, is potent,
exhibits high cutaneous bioavailability [26] and which
was, in addition, used in high concentration. It is also
noteworthy that the sites of predilection for AN (neck,
axillae and groin) were quite remote from the site where
the SVC assay was conducted viz., the volar aspect of the
forearm. Another possible explanation is that SVC may
be diminished in darker skin. However, we have found
that SVC was independent of ethnic origin (Study 2) in
which peoples of African, South Asian or mixed ancestry
participated and which provided a range of skin textures
and colours. The alternative explanation is that there is
reduced glucocorticoid sensitivity of dermal vasculature
among severely insulin -resistant individuals as character-
ized by high grade AN. Such reduced glucocorticoid
Figure 1 (a) Graph Shows the Distribution of SVC Response within each Grade of AN (Study 1 Data). (b) Graph Shows the Distribution of
SVC Response within each Grade of AN (Study 2 Data).
Table 6 Inflammatory markers, fasting glucose and triglycerides in controls and subjects with acanthosis nigricans
grade 4 (Study 1, N = 100)
Parameter N Median (Interquartile Range) p*
Control Acanthosis Grade 4
C-reactive protein (mg/L) 100 5.00 (0.00, 6.00)
n=3 2
11.00 (6.25, 24.75)
n=6 8
< 0.001
IL1 (pg/ml) 79 7.66 (0.20, 25.05) 3.17 (0.13, 12.95) 0.309
IL6 (pgml) 89 35.2 (22.2, 53.9) 30.1 (13.1, 42.8) 0.287
TNF-alpha (pg/ml) 88 8.52 (6.88, 14.00) 9.07 (8.12, 11.74) 0.603
Fasting Glucose (mg/dl) 86 79 (74, 84) 90 (77, 111) 0.011
Triglycerides (mg/dl) 87 82 (64, 104) 140 (82, 189) < 0.001
* Mann Whitney U Test
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the face of increased cortisol exposure in MS [13,14]
characteristic Cushingoid features, notably thin skin and
purpura are absent. Differential tissue sensitivity will also
explain another paradox.
One of the models of MS that has been recently
explored is that relating to over activity of an enzyme,
11beta-hydroxysteroid dehydrogenase type 1, which regen-
erates the natural active glucocorticoid cortisol in man
(corticosterone in rodents) from inactive cortisone (deoxy-
corticosterone in rodents). Mice over expressing the gene
for this enzyme in adipose tissue have metabolic and
phenotypic features of MS [27]. Treatment with a specific
inhibitor of the enzyme both reverses the metabolic
abnormalities of MS as well as also stops atherosclerotic
plaque progression [28]. The mouse model of MS in
which glucocorticoid is overproduced in some tissues is
not mutually exclusive of the findings demonstrated in our
study. In man the enzyme 11B-hydroxysteroid dehydro-
genase is active in mature adipocytes and hepatocytes and
may play a role in increasing glucocorticoid activity locally
in obesity syndromes [13]. Our work suggests that in the
face of increased glucocorticoid production in the liver
and adipose tissue reduced dermal glucocorticoid
Table 7 Parameter estimates for a generalized linear model with C-reactive protein as outcome variables
Parameter B Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Intercept 1.18 6.56 0.858 -11.90 14.26
BMI -0.38 0.28 0.181 -0.94 0.18
Age (years) 0.29 0.09 0.002 0.11 0.48
Glucose (mg/dl) -0.02 0.03 0.397 -0.08 0.03
Triglycerides (mg/dl) 0.04 0.02 0.008 0.01 0.08
Waist Circumference (cm) 0.04 0.09 0.673 -0.15 0.23
Acanthosis nigricans Grade 0 -0.64 3.32 0.847 -7.26 5.98
SVC 10.37 3.04 0.001 4.31 16.42
Acanthosis nigricans * SVC 10.10 3.39 0.004 -16.86 -3.34
Abbreviations: SVC = Skin vasoconstrictor assay to topical beclomethasone dipropionate;
BMI = Body mass index; ‘*’ = interaction
Figure 2 Model estimated marginal means of C-reactive protein at different levels of skin vasoconstrictor response to topical
beclomethasone dipropionate(SVC). SVC is classified as not present at all (= 0) or present (> = 1) for patients with and without acanthosis
nigricans [Study 1].
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response to counteract glucocorticoid overexposure i.e. tis-
sue- selective glucocorticoid resistance. In this regard, it is
well recognized that tissues can differentially regulate
glucocorticoid exposure both by enzyme-mediated [29] as
well as receptor-mediated mechanisms [30].
Glucocorticoid resistance, even if adaptive, will have
consequences. Given the natural anti-inflammatory
Figure 3 Acanthosis nigricans Grade 1.
Figure 4 Acanthosis nigricans Grade 2.
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matory phenomena could arise from this state of reduced
glucocorticoid activity. In keeping with this notion, we
have shown that not only was SVC an independent pre-
dictor of CRP but also those with combined AN and
absent SVC have the highest CRP levels (Figure 2). The
role of the vasculature in the immune response is well
documented [31] and elevated CRP reflects deficiency of
the innate immune system. It should be noted, however,
there was no obvious relationship between plasma cyto-
kines IL-1, IL-6 and TNF-alpha and the SVC among the
groups here studied. This implies that the exaggerated
inflammatory response, though more marked when SVC
is absent, is confined to innate or vascular mechanisms
without discernible changes involving cytokines.
There were some limitations to our studies. There was
an age disparity between subjects carefully selected for
having high grade AN in STUDY 1 when compared with
controls which could have been a confounding factor. In
the multivariate linear model which is based on data
from study 1, the interaction between SVC and AN may
also be mediated by those other covariates which are
imbalanced between the groups with and without AN
grade 4. However, in STUDY 2, where subjects were
Figure 5 Acanthosis nigricans Grade 3.
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nificant age difference in the groups, the association
between AN and absent SVC was sustained. Similarly,
analysis of data to evaluate the relationship between SVC
and ethnicity would not have been meaningful in Study
1, given the small numbers of Afro-Caribbeans (n = 17)
and “Others” (n = 10) but in Study 2 where this was pos-
sible, we found SVC to be independent of ethnicity. The
prevalence of AN is known to be ethnically related and
darker races exhibit higher prevalence [18]. It remains to
be seen if the SVC/AN relationship demonstrated among
Africans and Asian Indians occurs in other ethnic groups.
It should be noted that the frequency of SVC responsive-
ness also appears to be higher in Caucasians (90%) [16]
than among this sample comprising people with darker
skin. It is also unclear whether the absence of SVC
response to topical glucocorticoid represents a conse-
quence of inflammation or is indeed the cause of exag-
gerated inflammation.
The observation that acanthosis nigricans ameliorates
with progressive weight reduction [32] highlights the
role of obesity in its pathogenesis. It would be interest-
ing to determine whether SVC alters with weight reduc-
tion, which will indicate that glucocorticoid resistance in
MS is acquired and not genetic with obvious implica-
tions for interventional strategies.
The interactions between stress, inflammation, obesity
and the hypothalamic-pituitary-adrenal axis [7-10,33] are
complex and no doubt an evolving story. Differential
tissue sensitivity to glucocorticoids adds an additional
dimension to the list of abnormalities already known to
exist in the hypothalamic-pituitary-adrenal axis
[11,13,14,34] in the MS and the skin presents a valuable
and practical window through which such interactions can
be explored.
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